Skip to main content
Top
Published in: BMC Surgery 1/2018

Open Access 01-12-2018 | Research article

Perioperative dynamics and significance of plasma-free amino acid profiles in colorectal cancer

Authors: Kayoko Katayama, Akio Higuchi, Hiroshi Yamamoto, Atsuko Ikeda, Shinya Kikuchi, Manabu Shiozawa

Published in: BMC Surgery | Issue 1/2018

Login to get access

Abstract

Background

For early detection of cancer, we have previously developed the AminoIndex Cancer Screening (AICS) system, which quantifies 6 plasma-free amino acids (PFAAs) in blood samples. Herein, we examined the usefulness of the AICS in patients with colorectal cancer (CRC) by comparing the preoperative and postoperative PFAA profiles.

Methods

Our study cohort consisted of 62 patients who had undergone curative resection for CRC at our cancer center, with no recurrence at the time of the study. Blood samples were collected from fasted patients within 1 week before the resection and at 0.5–6.5 years post-resection. Following plasmapheresis, the PFAA levels were measured via liquid chromatography/mass spectrometry, and the AICS values were computed (the higher the value, the greater the probability of cancer). Risk was calculated from the AICS value and ranked as A, B, or C, with rank C representing the highest risk. All patients in our study were rank B + C.

Results

The postoperative AICS value was lower than the preoperative value in 57 of the 62 patients; the rank was also lower postoperatively (49 patients, p < 0.001). The decline in both was stage-independent, even occurring in patients with right-sided tumors or poorly differentiated adenocarcinomas. For comparative purposes, the levels of 2 tumor markers (carbohydrate antigen 19–9 and carcinoembryonic antigen) were also examined; these were within the reference ranges in 70–80% of patients preoperatively and in 80–90% postoperatively.

Conclusion

We suggest that tumor-bearing conditions alter the PFAA profiles, which may be used to predict prognosis and monitor for recurrence in CRC patients after tumor resection.

Trial registration

This trial has been retrospectively registered at UMIN-CTR R000028005, Oct 06, 2016.
Appendix
Available only for authorised users
Literature
1.
go back to reference Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2016;66:683–91.CrossRefPubMed Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2016;66:683–91.CrossRefPubMed
2.
go back to reference Ferlay JSI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. http://globocan.iarc.fr. Accessed 05 March 2017. Ferlay JSI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. http://​globocan.​iarc.​fr. Accessed 05 March 2017.
4.
go back to reference Hashiguchi Y, Matsuda K, Yamazaki S, Nozawa K, Fujii S. Current status of colorectal cancer examination and therapy. J Colon Exam. 2015;32:9–16. (Article in Japanese). Hashiguchi Y, Matsuda K, Yamazaki S, Nozawa K, Fujii S. Current status of colorectal cancer examination and therapy. J Colon Exam. 2015;32:9–16. (Article in Japanese).
5.
go back to reference Huang CM, Huang MY, Ma CJ, Yeh Y, Tsai HL, Huang CW, et al. Neoadjuvant FOLFOX chemotherapy combined with radiotherapy followed by radical resection in patients with locally advanced colon cancer. Radiat Oncol. 2017;12:48.CrossRefPubMedPubMedCentral Huang CM, Huang MY, Ma CJ, Yeh Y, Tsai HL, Huang CW, et al. Neoadjuvant FOLFOX chemotherapy combined with radiotherapy followed by radical resection in patients with locally advanced colon cancer. Radiat Oncol. 2017;12:48.CrossRefPubMedPubMedCentral
6.
go back to reference JASCCR. Guidelines 2014 for the treatment of colorectal cancer. Tokyo: Kanehara shuppan; 2014. JASCCR. Guidelines 2014 for the treatment of colorectal cancer. Tokyo: Kanehara shuppan; 2014.
7.
go back to reference Tokodai K, Narimatsu H, Nishida A, Takaya K, Hara Y, Kawagishi N, et al. Risk factors for recurrence in stage II/III colorectal cancer patients treated with curative surgery: the impact of postoperative tumor markers and an infiltrative growth pattern. J Surg Oncol. 2016;114:368–s74.CrossRefPubMed Tokodai K, Narimatsu H, Nishida A, Takaya K, Hara Y, Kawagishi N, et al. Risk factors for recurrence in stage II/III colorectal cancer patients treated with curative surgery: the impact of postoperative tumor markers and an infiltrative growth pattern. J Surg Oncol. 2016;114:368–s74.CrossRefPubMed
8.
go back to reference Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, et al. Japanese Society for Cancer of the colon and Rectum (JSCCR) guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol. 2015;20:207–39.CrossRefPubMedPubMedCentral Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, et al. Japanese Society for Cancer of the colon and Rectum (JSCCR) guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol. 2015;20:207–39.CrossRefPubMedPubMedCentral
9.
go back to reference Ravaglia G, Forti P, Maioli F, Bianchi G, Martelli M, Talerico T, et al. Plasma amino acid concentrations in patients with amnestic mild cognitive impairment or Alzheimer disease. Am J Clin Nutr. 2004;80:483–8.CrossRefPubMed Ravaglia G, Forti P, Maioli F, Bianchi G, Martelli M, Talerico T, et al. Plasma amino acid concentrations in patients with amnestic mild cognitive impairment or Alzheimer disease. Am J Clin Nutr. 2004;80:483–8.CrossRefPubMed
10.
go back to reference Suliman ME, Qureshi AR, Stenvinkel P, Pecoits-Filho R, Barany P, Heimburger O, et al. Inflammation contributes to low plasma amino acid concentrations in patients with chronic kidney disease. Am J Clin Nutr. 2005;82:342–9.CrossRefPubMed Suliman ME, Qureshi AR, Stenvinkel P, Pecoits-Filho R, Barany P, Heimburger O, et al. Inflammation contributes to low plasma amino acid concentrations in patients with chronic kidney disease. Am J Clin Nutr. 2005;82:342–9.CrossRefPubMed
11.
go back to reference Kimura T, Noguchi Y, Shikata N, Takahashi M. Plasma amino acid analysis for diagnosis and amino acid-based metabolic networks. Curr Opin Clin Nutr Metab Care. 2009;12:49–53.CrossRefPubMed Kimura T, Noguchi Y, Shikata N, Takahashi M. Plasma amino acid analysis for diagnosis and amino acid-based metabolic networks. Curr Opin Clin Nutr Metab Care. 2009;12:49–53.CrossRefPubMed
12.
go back to reference Noguchi Y, Zhang QW, Sugimoto T, Furuhata Y, Sakai R, Mori M, et al. Network analysis of plasma and tissue amino acids and the generation of an amino index for potential diagnostic use. Am J Clin Nutr. 2006;83:513s–9s.CrossRefPubMed Noguchi Y, Zhang QW, Sugimoto T, Furuhata Y, Sakai R, Mori M, et al. Network analysis of plasma and tissue amino acids and the generation of an amino index for potential diagnostic use. Am J Clin Nutr. 2006;83:513s–9s.CrossRefPubMed
13.
go back to reference Miyagi Y, Higashiyama M, Gochi A, Akaike M, Ishikawa T, Miura T, et al. Plasma free amino acid profiling of five types of cancer patients and its application for early detection. PLoS One. 2011;6:e24143.CrossRefPubMedPubMedCentral Miyagi Y, Higashiyama M, Gochi A, Akaike M, Ishikawa T, Miura T, et al. Plasma free amino acid profiling of five types of cancer patients and its application for early detection. PLoS One. 2011;6:e24143.CrossRefPubMedPubMedCentral
14.
go back to reference Okamoto N. Use of “AminoIndex technology” for cancer screening. Ningen Dock. 2012;26:911–22. Okamoto N. Use of “AminoIndex technology” for cancer screening. Ningen Dock. 2012;26:911–22.
15.
go back to reference Miyagi Y, Higashiyama M, Gochi A, Ishikawa T, Saruki N, Akaike M, Bando E, et al. Clinical Utility of AminoIndex Cancer Screening (AICS) for Early Detection of Various Cancers in Comparison with Detection Using Tumor Markers. Ningen Dock. 2014;29:585–591. (Article in Japanese). Miyagi Y, Higashiyama M, Gochi A, Ishikawa T, Saruki N, Akaike M, Bando E, et al. Clinical Utility of AminoIndex Cancer Screening (AICS) for Early Detection of Various Cancers in Comparison with Detection Using Tumor Markers. Ningen Dock. 2014;29:585–591. (Article in Japanese).
16.
go back to reference Fukutake N, Ueno M, Hiraoka N, Shimada K, Shiraishi K, Saruki N, et al. A novel multivariate index for pancreatic cancer detection based on the plasma free amino acid profile. PLoS One. 2015;10:e0132223.CrossRefPubMedPubMedCentral Fukutake N, Ueno M, Hiraoka N, Shimada K, Shiraishi K, Saruki N, et al. A novel multivariate index for pancreatic cancer detection based on the plasma free amino acid profile. PLoS One. 2015;10:e0132223.CrossRefPubMedPubMedCentral
17.
go back to reference Shimbo K, Kubo S, Harada Y, Oonuki T, Yokokura T, Yoshida H, et al. Automated precolumn derivatization system for analyzing physiological amino acids by liquid chromatography/mass spectrometry. Biomed Chromatogr. 2010;24:683–91.CrossRefPubMed Shimbo K, Kubo S, Harada Y, Oonuki T, Yokokura T, Yoshida H, et al. Automated precolumn derivatization system for analyzing physiological amino acids by liquid chromatography/mass spectrometry. Biomed Chromatogr. 2010;24:683–91.CrossRefPubMed
18.
go back to reference Shimbo K, Yahashi A, Hirayama K, Nakazawa M, Miyano H. Multifunctional and highly sensitive precolumn reagents for amino acids in liquid chromatography/tandem mass spectrometry. Anal Chem. 2009;81:5172–9.CrossRefPubMed Shimbo K, Yahashi A, Hirayama K, Nakazawa M, Miyano H. Multifunctional and highly sensitive precolumn reagents for amino acids in liquid chromatography/tandem mass spectrometry. Anal Chem. 2009;81:5172–9.CrossRefPubMed
19.
go back to reference Shimbo K, Oonuki T, Yahashi A, Hirayama K, Miyano H. Precolumn derivatization reagents for high-speed analysis of amines and amino acids in biological fluid using liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom. 2009;23:1483–92.CrossRefPubMed Shimbo K, Oonuki T, Yahashi A, Hirayama K, Miyano H. Precolumn derivatization reagents for high-speed analysis of amines and amino acids in biological fluid using liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom. 2009;23:1483–92.CrossRefPubMed
20.
go back to reference Toiyama Y, Miki C, Inoue Y, Tanaka K, Mohri Y, Kusunoki M. Evaluation of an inflammation-based prognostic score for the identification of patients requiring postoperative adjuvant chemotherapy for stage II colorectal cancer. Exp Ther Med. 2011;2:95–101.CrossRefPubMed Toiyama Y, Miki C, Inoue Y, Tanaka K, Mohri Y, Kusunoki M. Evaluation of an inflammation-based prognostic score for the identification of patients requiring postoperative adjuvant chemotherapy for stage II colorectal cancer. Exp Ther Med. 2011;2:95–101.CrossRefPubMed
21.
go back to reference Luo Y, Yoneda J, Ohmori H, Sasaki T, Shimbo K, Eto S, et al. Cancer usurps skeletal muscle as an energy repository. Cancer Res. 2014;74:330–40.CrossRefPubMed Luo Y, Yoneda J, Ohmori H, Sasaki T, Shimbo K, Eto S, et al. Cancer usurps skeletal muscle as an energy repository. Cancer Res. 2014;74:330–40.CrossRefPubMed
22.
go back to reference Hisamatsu T, Okamoto S, Hashimoto M, Muramatsu T, Andou A, Uo M, et al. Novel, objective, multivariate biomarkers composed of plasma amino acid profiles for the diagnosis and assessment of inflammatory bowel disease. PLoS One. 2012;7:e31131.CrossRefPubMedPubMedCentral Hisamatsu T, Okamoto S, Hashimoto M, Muramatsu T, Andou A, Uo M, et al. Novel, objective, multivariate biomarkers composed of plasma amino acid profiles for the diagnosis and assessment of inflammatory bowel disease. PLoS One. 2012;7:e31131.CrossRefPubMedPubMedCentral
23.
go back to reference Gu Y, Chen T, Fu S, Sun X, Wang L, Wang J, et al. Perioperative dynamics and significance of amino acid profiles in patients with cancer. J Transl Med. 2015;13:35.CrossRefPubMedPubMedCentral Gu Y, Chen T, Fu S, Sun X, Wang L, Wang J, et al. Perioperative dynamics and significance of amino acid profiles in patients with cancer. J Transl Med. 2015;13:35.CrossRefPubMedPubMedCentral
24.
go back to reference Minet-Quinard R, Van Praagh I, Kwiatkowski F, Beaujon G, Feillel V, Beaufrere B, et al. Pre- and postoperative aminoacidemia in breast cancer: a study vs. matched healthy subjects. Cancer Investig. 2004;22:203–10.CrossRef Minet-Quinard R, Van Praagh I, Kwiatkowski F, Beaujon G, Feillel V, Beaufrere B, et al. Pre- and postoperative aminoacidemia in breast cancer: a study vs. matched healthy subjects. Cancer Investig. 2004;22:203–10.CrossRef
25.
go back to reference Loupakis F, Yang D, Yau L, Feng S, Cremolini C, Zhang W, et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst. 2015;107(3) Loupakis F, Yang D, Yau L, Feng S, Cremolini C, Zhang W, et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst. 2015;107(3)
26.
go back to reference Venook AP, Niedzwiecki D, Lopatin M, Ye X, Lee M, Friedman PN, et al. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol. 2013;31:1775–81.CrossRefPubMedPubMedCentral Venook AP, Niedzwiecki D, Lopatin M, Ye X, Lee M, Friedman PN, et al. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol. 2013;31:1775–81.CrossRefPubMedPubMedCentral
27.
go back to reference Benson AB 3rd, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS, et al. Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15:370–98.CrossRef Benson AB 3rd, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS, et al. Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15:370–98.CrossRef
28.
go back to reference Venook AP, Niedzwiecki D, Innocenti F, Fruth B, Greene C, O'Neil BH, et al. Impact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC). Analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol. 2016;34 Suppl;abstr 3504. Venook AP, Niedzwiecki D, Innocenti F, Fruth B, Greene C, O'Neil BH, et al. Impact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC). Analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol. 2016;34 Suppl;abstr 3504.
30.
go back to reference Ychou M, Riviore M, Thezenas S, Guimbaud R, Ghiringhelli F, Mercier-Blas A, et al. FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized Study—Prodige 14 – ACCORD 21 (METHEP-2), a unicancer GI trial. J Clin Oncol. 2016;34 Suppl:abstr 3512. Ychou M, Riviore M, Thezenas S, Guimbaud R, Ghiringhelli F, Mercier-Blas A, et al. FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized Study—Prodige 14 – ACCORD 21 (METHEP-2), a unicancer GI trial. J Clin Oncol. 2016;34 Suppl:abstr 3512.
Metadata
Title
Perioperative dynamics and significance of plasma-free amino acid profiles in colorectal cancer
Authors
Kayoko Katayama
Akio Higuchi
Hiroshi Yamamoto
Atsuko Ikeda
Shinya Kikuchi
Manabu Shiozawa
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Surgery / Issue 1/2018
Electronic ISSN: 1471-2482
DOI
https://doi.org/10.1186/s12893-018-0344-0

Other articles of this Issue 1/2018

BMC Surgery 1/2018 Go to the issue